A Pilot Double-Blind Randomized Trial of Perampanel for Essential Tremor.
AMPA‐type receptor antagonist
essential tremor
perampanel
randomized controlled trial
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
07
11
2019
revised:
25
01
2020
accepted:
10
02
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
epublish
Résumé
Perampanel is a noncompetitive antagonist of alpha-amino-3-hydroxy-5-methylisoxazole propionic acid glutamate receptors suggested to modulate tremor. To assess the efficacy and tolerability of perampanel for essential tremor. This was a double-blind, placebo-controlled, randomized, cross-over trial involving 26 patients titrated to 8 mg/day or a lower maximally tolerated dose as monotherapy or adjunct to antitremor medication. Tremor was assessed at the beginning and end of each 14-week treatment arm. The primary endpoint was change in the videotaped performance subscale of The Essential Tremor Rating Assessment Scale, scored by a blinded rater. Secondary endpoints included change in The Essential Tremor Rating Assessment Scale Activity of Daily Living and Quality of Life in Essential Tremor and Subject Global Impression of Change subscales. Data are available for 15 and 11 participants who completed placebo and perampanel arms, respectively. Perampanel was superior to placebo on the primary endpoint ( These findings suggest that perampanel exerts efficacy for some persons with essential tremor, but this population appears prone to adverse events.
Sections du résumé
BACKGROUND
BACKGROUND
Perampanel is a noncompetitive antagonist of alpha-amino-3-hydroxy-5-methylisoxazole propionic acid glutamate receptors suggested to modulate tremor.
OBJECTIVES
OBJECTIVE
To assess the efficacy and tolerability of perampanel for essential tremor.
METHODS
METHODS
This was a double-blind, placebo-controlled, randomized, cross-over trial involving 26 patients titrated to 8 mg/day or a lower maximally tolerated dose as monotherapy or adjunct to antitremor medication. Tremor was assessed at the beginning and end of each 14-week treatment arm. The primary endpoint was change in the videotaped performance subscale of The Essential Tremor Rating Assessment Scale, scored by a blinded rater. Secondary endpoints included change in The Essential Tremor Rating Assessment Scale Activity of Daily Living and Quality of Life in Essential Tremor and Subject Global Impression of Change subscales.
RESULTS
RESULTS
Data are available for 15 and 11 participants who completed placebo and perampanel arms, respectively. Perampanel was superior to placebo on the primary endpoint (
CONCLUSIONS
CONCLUSIONS
These findings suggest that perampanel exerts efficacy for some persons with essential tremor, but this population appears prone to adverse events.
Identifiants
pubmed: 32373656
doi: 10.1002/mdc3.12927
pii: MDC312927
pmc: PMC7197304
doi:
Types de publication
Journal Article
Langues
eng
Pagination
399-404Informations de copyright
© 2020 International Parkinson and Movement Disorder Society.
Déclaration de conflit d'intérêts
The study was funded by Eisai, Inc. and supported by the U.S. Department of Veterans Affairs. The authors declare that there are no conflicts of interest relevant to this work.
Références
Acta Neurochir (Wien). 2012 Mar;154(3):495-9
pubmed: 22109693
Parkinsonism Relat Disord. 2012 Nov;18(9):1042-4
pubmed: 22703869
Tremor Other Hyperkinet Mov (N Y). 2018 Oct 11;8:600
pubmed: 31637097
Epilepsy Res. 2015 Feb;110:216-20
pubmed: 25616475
J Physiol. 2006 Feb 15;571(Pt 1):101-20
pubmed: 16357010
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S115-8
pubmed: 26343494
Tremor Other Hyperkinet Mov (N Y). 2018 Apr 17;8:552
pubmed: 29686940
Parkinsonism Relat Disord. 2005 Sep;11(6):367-73
pubmed: 16103000
Parkinsonism Relat Disord. 2019 Mar;60:171-172
pubmed: 30318448
Lancet Neurol. 2011 Feb;10(2):148-61
pubmed: 21256454
Eur J Neurol. 2010 Jun 1;17(6):882-4
pubmed: 20067514
J Pharmacol Exp Ther. 2013 Oct;347(1):212-24
pubmed: 23899905
Mov Disord. 2012 Oct;27(12):1567-9
pubmed: 23032792
Mov Disord. 2009 Aug 15;24(11):1629-35
pubmed: 19514010
Ther Adv Neurol Disord. 2013 Jul;6(4):229-36
pubmed: 23858326
Mov Disord. 2010 Apr 15;25(5):634-8
pubmed: 20201005
Neurology. 2018 Aug 7;91(6):e543-e550
pubmed: 29970404
J Neurophysiol. 2002 Apr;87(4):1993-2008
pubmed: 11929918
Sleep Med. 2017 Jun;34:105-108
pubmed: 28522077
Eur J Pharmacol. 2009 Aug 15;616(1-3):73-80
pubmed: 19497322
Epilepsia. 2014 Jan;55 Suppl 1:13-5
pubmed: 24400692
Bioorg Med Chem. 2002 May;10(5):1627-37
pubmed: 11886824
EJNMMI Res. 2017 Aug 16;7(1):63
pubmed: 28815446
Acta Neurol Scand. 2018 Apr;137(4):378-391
pubmed: 29214650
J Neurol. 2018 Apr;265(4):733-740
pubmed: 29159466
J Neurophysiol. 1996 Jul;76(1):255-75
pubmed: 8836223
Mov Disord. 2019 Jul;34(7):950-958
pubmed: 31046186
Neurology. 2006 Mar 14;66(5):672-7
pubmed: 16436648